- Risk of Hepatitis B Virus (HBV) Reactivation in HBsAg-Negative, Anti-HBc-Negative Patients Receiving Rituximab for Autoimmune Diseases in HBV Endemic Areas
-
Lan TY, Lin YC, Tseng TC, Yang HC, Kao JH, Cheng CF, Lee TJ, Huang SC, Lu CH, Li KJ, Hsieh SC
- KMID: 2540417
- Gut Liver.
- 2023 Mar;17(2):288-298.
- doi: 10.5009/gnl210551
Background/Aims: Rituximab is known to be associated with high hepatitis B virus (HBV) reactivation rate in patients with resolved HBV infection and hematologic malignancy. However, data regarding HBV reactivation (HBVr) in... -
- CITED
-
- Close
- SHARE
-
- Close
